Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.05 +0.5%	$1.96	$1.41 ▼ $2.79	$92.72M	1.46	67,158 shs	44,516 shs
FBRX Forte Biosciences	$10.18 +2.2%	$10.70	$4.11 ▼ $28.68	$65.57M	2.97	174,543 shs	26,851 shs
JATT JATT Acquisition	$1.96 +51.9%	$1.17	$7.80 ▼ $12.38	$140.76M	N/A	41,322 shs	7.83 million shs
ZURA Zura Bio	$1.91 -2.6%	$1.18	$0.97 ▼ $5.07	$134.01M	-0.1	511,697 shs	3.70 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	0.00%	+11.17%	-0.78%	+13.97%	+7.94%
FBRX Forte Biosciences	+2.89%	-13.01%	-19.55%	+35.69%	+42,831.03%
JATT JATT Acquisition	0.00%	-3.70%	+8.33%	+5.69%	-62.86%
ZURA Zura Bio	+51.94%	+41.01%	+71.93%	+59.35%	-44.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTX Entera Bio	2.9448 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.8	0.0
FBRX Forte Biosciences	3.3927 of 5 stars	3.5	5.0	0.0	0.0	2.9	1.7	0.6
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	3.0461 of 5 stars	3.6	3.0	0.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	3.00	Buy	$10.00	387.80% Upside
FBRX Forte Biosciences	3.00	Buy	$61.00	499.21% Upside
JATT JATT Acquisition	0.00	N/A	N/A	N/A
ZURA Zura Bio	3.13	Buy	$14.33	650.44% Upside

Current Analyst Ratings Breakdown

Latest JATT, FBRX, ZURA, and ENTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$180K	517.63	N/A	N/A	$0.23 per share	8.91
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
JATT JATT Acquisition	N/A	N/A	$0.07 per share	27.08	($0.53) per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$9.54M	-$0.26	0.00	N/A	N/A	-4,525.11%	-95.10%	-82.77%	8/8/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	0.00	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest JATT, FBRX, ZURA, and ENTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	FBRX Forte Biosciences	-$1.21	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ZURA Zura Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	ENTX Entera Bio	-$0.11	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/9/2025	Q1 2025	ENTX Entera Bio	-$0.07	-$0.06	+$0.01	-$0.06	N/A	$0.04 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	13.07	13.07
FBRX Forte Biosciences	N/A	5.22	5.22
JATT JATT Acquisition	N/A	0.15	0.15
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
FBRX Forte Biosciences	77.63%
JATT JATT Acquisition	47.97%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.38%
FBRX Forte Biosciences	5.90%
JATT JATT Acquisition	20.00%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	20	45.45 million	40.73 million	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

JATT, FBRX, ZURA, and ENTX Headlines

Recent News About These Companies

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18 at 12:55 PM | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18 at 2:04 AM | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of "Buy" from Analysts

July 13, 2025 | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by Analysts

July 13, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Stock Price Up 12.5% - Should You Buy?

July 10, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What Happened

July 10, 2025 | marketbeat.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Buy" by Analysts

June 18, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 25, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT, FBRX, ZURA, and ENTX Company Descriptions

Entera Bio NASDAQ:ENTX

$2.05 +0.01 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.09 +0.04 (+2.15%)

As of 04:47 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Forte Biosciences NASDAQ:FBRX

$10.18 +0.22 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$10.25 +0.07 (+0.70%)

As of 07:56 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

JATT Acquisition NYSE:JATT

$1.96 +0.67 (+51.94%)

As of 07/17/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Zura Bio NASDAQ:ZURA

$1.91 -0.05 (-2.55%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 +0.03 (+1.57%)

As of 07:57 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time